Profile of maraviroc: a CCR5 antagonist in the management of treatment-experienced HIV patients

Thore LorenzenIFI Institute for Interdisciplinary Medicine, Hamburg, GermanyAbstract: Maraviroc is the first and, so far, the only licensed representative of the class of chemokine receptor type 5 (CCR5) inhibitors used for the treatment of human immunodeficiency virus (HIV) infection. Its safety an...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Thore Lorenzen
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/905b7ba498134757a0babd806097faed
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:905b7ba498134757a0babd806097faed
record_format	dspace
spelling	oai:doaj.org-article:905b7ba498134757a0babd806097faed2021-12-02T05:05:45ZProfile of maraviroc: a CCR5 antagonist in the management of treatment-experienced HIV patients1179-1373https://doaj.org/article/905b7ba498134757a0babd806097faed2010-08-01T00:00:00Zhttp://www.dovepress.com/profile-of-maraviroc-a-ccr5-antagonist-in-the-management-of-treatment--a5091https://doaj.org/toc/1179-1373Thore LorenzenIFI Institute for Interdisciplinary Medicine, Hamburg, GermanyAbstract: Maraviroc is the first and, so far, the only licensed representative of the class of chemokine receptor type 5 (CCR5) inhibitors used for the treatment of human immunodeficiency virus (HIV) infection. Its safety and efficacy were demonstrated in several clinical trials, and its use was approved in 2007 by the responsible authorities. Some specific issues are correlated with maraviroc and its use. It is the only drug in the antiretroviral armamentarium, which does not interact with the viral enzymes but with a human receptor. Hence, it is able to be long-term effective only if the infecting virus uses, exclusively, the CCR5 receptor. Occurrence and detection of the CCR5 tropism are some of the great challenges of maraviroc use in treatment-experienced patients. Although up to 80% of naive patients harbor CCR5-tropic virus, the occurrence of CXCR4 or other tropisms increases with the duration of HIV infection and treatment. Nonetheless, maraviroc is a potent medication for eligible patients and helps to improve the outcome of antiretroviral treatment (ART) of HIV infection.Keywords: CCR5 inhibitor, HIV infection, treatment-experienced patients, tropism Thore LorenzenDove Medical PressarticleImmunologic diseases. AllergyRC581-607ENHIV/AIDS: Research and Palliative Care, Vol 2010, Iss default, Pp 151-156 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Immunologic diseases. Allergy RC581-607
spellingShingle	Immunologic diseases. Allergy RC581-607 Thore Lorenzen Profile of maraviroc: a CCR5 antagonist in the management of treatment-experienced HIV patients
description	Thore LorenzenIFI Institute for Interdisciplinary Medicine, Hamburg, GermanyAbstract: Maraviroc is the first and, so far, the only licensed representative of the class of chemokine receptor type 5 (CCR5) inhibitors used for the treatment of human immunodeficiency virus (HIV) infection. Its safety and efficacy were demonstrated in several clinical trials, and its use was approved in 2007 by the responsible authorities. Some specific issues are correlated with maraviroc and its use. It is the only drug in the antiretroviral armamentarium, which does not interact with the viral enzymes but with a human receptor. Hence, it is able to be long-term effective only if the infecting virus uses, exclusively, the CCR5 receptor. Occurrence and detection of the CCR5 tropism are some of the great challenges of maraviroc use in treatment-experienced patients. Although up to 80% of naive patients harbor CCR5-tropic virus, the occurrence of CXCR4 or other tropisms increases with the duration of HIV infection and treatment. Nonetheless, maraviroc is a potent medication for eligible patients and helps to improve the outcome of antiretroviral treatment (ART) of HIV infection.Keywords: CCR5 inhibitor, HIV infection, treatment-experienced patients, tropism
format	article
author	Thore Lorenzen
author_facet	Thore Lorenzen
author_sort	Thore Lorenzen
title	Profile of maraviroc: a CCR5 antagonist in the management of treatment-experienced HIV patients
title_short	Profile of maraviroc: a CCR5 antagonist in the management of treatment-experienced HIV patients
title_full	Profile of maraviroc: a CCR5 antagonist in the management of treatment-experienced HIV patients
title_fullStr	Profile of maraviroc: a CCR5 antagonist in the management of treatment-experienced HIV patients
title_full_unstemmed	Profile of maraviroc: a CCR5 antagonist in the management of treatment-experienced HIV patients
title_sort	profile of maraviroc: a ccr5 antagonist in the management of treatment-experienced hiv patients
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/905b7ba498134757a0babd806097faed
work_keys_str_mv	AT thorelorenzen profileofmaravirocaccr5antagonistinthemanagementoftreatmentexperiencedhivpatients
_version_	1718400605005807616

Profile of maraviroc: a CCR5 antagonist in the management of treatment-experienced HIV patients

Ejemplares similares